BACKGROUND: There is an increased risk of new basal cell carcinomas (BCCs) developing in a person who has had a BCC. OBJECTIVE: This study attempts to define the magnitude of this increased risk. METHODS: The charts of 260 white patients with a histologically proven BCC were reviewed for the occurrence of new BCCs. The cumulative 5-year incidence (modified life-table method) for new BCCs developing in these patients was compared with the 5-year incidence in the general white population of the United States. RESULTS: Of the 260 patients, new BCCs developed in 137 within an average of 38.3 months, a 5-year cumulative rate of one or more new BCCs of 45.2%. The yearly risk for new BCCs developing in the study population remained high during the 5-year interval. In the general white population of the United States, the maximal 5-year incidence was calculated to be 5% (p < 0.005, chi-square test). CONCLUSION: Patients with a history of BCC require life-long follow-up because of the high probability of new BCCs developing.
BACKGROUND: There is an increased risk of new basal cell carcinomas (BCCs) developing in a person who has had a BCC. OBJECTIVE: This study attempts to define the magnitude of this increased risk. METHODS: The charts of 260 white patients with a histologically proven BCC were reviewed for the occurrence of new BCCs. The cumulative 5-year incidence (modified life-table method) for new BCCs developing in these patients was compared with the 5-year incidence in the general white population of the United States. RESULTS: Of the 260 patients, new BCCs developed in 137 within an average of 38.3 months, a 5-year cumulative rate of one or more new BCCs of 45.2%. The yearly risk for new BCCs developing in the study population remained high during the 5-year interval. In the general white population of the United States, the maximal 5-year incidence was calculated to be 5% (p < 0.005, chi-square test). CONCLUSION:Patients with a history of BCC require life-long follow-up because of the high probability of new BCCs developing.
Authors: Kunal C Kadakia; Debra L Barton; Charles L Loprinzi; Jeff A Sloan; Clark C Otley; Brent B Diekmann; Paul J Novotny; Steven R Alberts; Paul J Limburg; Mark R Pittelkow Journal: Cancer Date: 2011-08-31 Impact factor: 6.860
Authors: David B Buller; Barbara J Walkosz; Peter A Andersen; Michael D Scott; Gary R Cutter Journal: Transl Behav Med Date: 2015-06-06 Impact factor: 3.046
Authors: David B Buller; Peter A Andersen; Barbara J Walkosz; Michael D Scott; Larry Beck; Gary R Cutter Journal: Contemp Clin Trials Date: 2015-11-22 Impact factor: 2.226
Authors: Louise K Mercer; Adele C Green; James B Galloway; Rebecca Davies; Mark Lunt; William G Dixon; Kath D Watson; Deborah P M Symmons; Kimme L Hyrich Journal: Ann Rheum Dis Date: 2012-01-12 Impact factor: 19.103